Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1997 Mar;74(3):158-61.

Prevalence of antituberculosis drug resistance in Harar Tuberculosis Centre, Ethiopia

Affiliations
  • PMID: 9185412
Comparative Study

Prevalence of antituberculosis drug resistance in Harar Tuberculosis Centre, Ethiopia

G Mitike et al. East Afr Med J. 1997 Mar.

Abstract

A tuberculosis centre based, cross sectional study was carried out in order to describe the magnitude of anti-tuberculosis drug resistance in Harar, eastern Ethiopia. The study was conducted in Harar Tuberculosis Centre which is the major tuberculosis treatment centre in eastern Ethiopia. A total of 338 smear/culture positive patients were enrolled in the study between October 10, 1994 and January 20, 1995. Exposure status was determined through interview; drug resistance was determined through laboratory investigation. The overall prevalence of resistance to one or more antituberculosis drugs was 126/338(37.3%). Initial and acquired resistance were 82/252(32.5%) and 44/86(51.2%) respectively. Multi-drug resistance (resistance to both isoniazid and rifampicin) was detected in 3.5% of cases who had previous history of treatment. Anti-tuberculosis drug resistance was significantly higher in those who had previous history treatment (p < 0.005). The prevalence of drug resistance is high in Harar. There is a need for periodic drug resistance survey. Implementation of the WHO recommended supervised treatment with multi-sectoral approach is suggested.

PubMed Disclaimer

Publication types